SOD1 and amyotrophic lateral sclerosis: Nonetheless, although the antibody cannot override the many pathological pathways that occur in the motor neuron and in non-neuronal cells, this therapeutic approach has a potent effect on the course of disease, reducing synaptic loss, improving motor output and extending the lifespan of SOD1-G93A mice longer than riluzole, the long-standing FDA approved treatment for ALS (Jablonski et al., 2014).